Back to Search
Start Over
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
- Source :
- The Lancet HIV; April 2018, Vol. 5 Issue: 4 pe162-e171, 10p
- Publication Year :
- 2018
-
Abstract
- Abacavir and tenofovir alafenamide offer reduced bone toxicity compared with tenofovir disoproxil fumarate. We aimed to compare safety and efficacy of tenofovir alafenamide plus emtricitabine with that of abacavir plus lamivudine.
Details
- Language :
- English
- ISSN :
- 24054704 and 23523018
- Volume :
- 5
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- The Lancet HIV
- Publication Type :
- Periodical
- Accession number :
- ejs44867666
- Full Text :
- https://doi.org/10.1016/S2352-3018(18)30010-9